Pacific BiosciencesPACB
PACB
About: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Employees: 796
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
64% more call options, than puts
Call options by funds: $6.83M | Put options by funds: $4.17M
20% more capital invested
Capital invested by funds: $396M [Q3] → $477M (+$81.1M) [Q4]
20% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 64
9.45% more ownership
Funds ownership: 85.33% [Q3] → 94.78% (+9.45%) [Q4]
9% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 35
0% less funds holding
Funds holding: 226 [Q3] → 225 (-1) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 2 (-2) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1.50
30%
upside
Avg. target
$2
74%
upside
High target
$2.50
117%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
Scotiabank Sung Ji Nam 12% 1-year accuracy 3 / 25 met price target | 74%upside $2 | Sector Outperform Maintained | 25 Mar 2025 |
Piper Sandler David Westenberg 44% 1-year accuracy 19 / 43 met price target | 74%upside $2 | Neutral Reiterated | 20 Feb 2025 |
Goldman Sachs Matthew Sykes 43% 1-year accuracy 16 / 37 met price target | 30%upside $1.50 | Neutral Maintained | 18 Feb 2025 |
Stephens & Co. Mason Carrico 18% 1-year accuracy 5 / 28 met price target | 117%upside $2.50 | Overweight Reiterated | 18 Feb 2025 |
Financial journalist opinion
Based on 6 articles about PACB published over the past 30 days
Neutral
Market Watch
5 days ago
Pacific Biosciences Names Jim Gibson Chief Financial Officer
Pacific Biosciences of California has hired Jim Gibson as its new chief financial officer, effective March 31.
Neutral
GlobeNewsWire
5 days ago
Jim Gibson to join PacBio as Chief Financial Officer
MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations.
Neutral
Zacks Investment Research
1 week ago
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
Pacific Biosciences of California (PACB) reachead $1.26 at the closing of the latest trading day, reflecting a +0.8% change compared to its last close.
Positive
Zacks Investment Research
1 week ago
Here's Why You Should Retain PacBio Stock in Your Portfolio Now
PACB continues to deliver growth from its unique technologies amid macroeconomic concerns.
Neutral
GlobeNewsWire
2 weeks ago
Scientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes
MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for analyzing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilizes Paraphase, an informatics tool that, when paired with HiFi long-read sequencing, allows for high-precision variant detection and copy number analysis in 316 previously inaccessible segmental duplication regions, including 9 challenging medically-relevant genes.
Neutral
Zacks Investment Research
2 weeks ago
Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Pacific Biosciences of California (PACB) stood at $1.22, denoting a +1.67% change from the preceding trading day.
Negative
Seeking Alpha
1 month ago
Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock
Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock
Neutral
GlobeNewsWire
1 month ago
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 PM ET (12:10 PM PT) in Boston, MA.
Neutral
GlobeNewsWire
1 month ago
PacBio Grants Equity Incentive Award to New Employee
MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the “Option”) covering 400,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 300,000 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”), effective on February 10, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance with Nasdaq Marketplace Rule 5635(c)(4).
Neutral
Zacks Investment Research
1 month ago
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall
Despite strong Service and other revenues, PacBio reports soft fourth-quarter 2024 results partly due to lower Revio system shipments.
Charts implemented using Lightweight Charts™